Fisetin inhibits the proliferation, migration and invasion of pancreatic cancer by targeting PI3K/AKT/mTOR signaling

Pancreatic Cancer is an extremely malignant digestive tract tumor. With the increase of chemotherapeutic resistance of pancreatic Cancer, clinical treatment is in a dilemma. Hence, it is pivotal to design an effective drug for treating individuals with pancreatic Cancer. Fisetin extracted from vegetables, as well as fruits was explored to possess antioxidant, anti-cancer, anti-inflammatory along with anti-microbial properties. Nonetheless, there is limited research focusing on the utility of fisetin as an inhibitor of pancreatic Cancer. Similarly, the mechanism through which Fisetin dampens pancreatic Cancer remains unknown. This research work systematically evaluated the possible anti-cancer influences of fisetin in pancreatic Cancer, as well as explored its responsible molecular mechanism. Our data revealed that fisetin obviously dampens pancreatic Cancer progress in vitro along with in vivo dose-dependently. Furthermore, we established that fisetin repressed pancreatic Cancer via explicitly targeting PI3K/Akt/mTOR signaling cascade and not the JAK2 cascade. Our data clarified that fisetin is a prospective anti-cancer drug for pancreatic Cancer, as well as indicated the distinct molecular target of fisetin.